• Nystatin (Fungicidin): Reliable Antifungal Solutions for Res

  2026-05-13

  This article explores laboratory scenarios where Nystatin (Fungicidin) (SKU B1993) delivers reproducible, data-driven solutions to common assay challenges. It highlights validated use cases and protocol guidance for biomedical researchers, emphasizing the product’s compatibility, rigor, and evidence-backed performance.

• hiPSC-Derived Intestinal Organoids Enable Human Pharmacokine

  2026-05-12

  This study establishes a streamlined protocol for generating human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) with high proliferative and differentiation capacity. The resulting organoids provide a more physiologically relevant in vitro model for pharmacokinetic and drug metabolism research, overcoming limitations of animal models and conventional cell lines.

• Lipid Nanoparticle Structure and Administration Shape mRNA D

  2026-05-12

  Chaudhary et al. provide key insights into how the structure of lipid nanoparticles (LNPs) and the route of administration influence the potency, immunogenicity, and maternal-fetal safety of mRNA therapies during pregnancy. Their work delivers mechanistic guidance for designing LNP-mRNA systems, addressing a critical gap in safe RNA-based interventions for pregnancy-related disorders.

• O-GlcNAcylation Regulates Ferroptosis and Trophoblast Syncyt

  2026-05-11

  This study uncovers how O-GlcNAc modification of HUWE1 orchestrates the ubiquitination of transferrin receptor 1 (TfR1), regulating iron uptake, ferroptosis, and syncytialization in placental trophoblasts during preeclampsia. The findings establish O-GlcNAcylation as a pivotal modulator of placental pathology and suggest new mechanistic targets for mitigating adverse pregnancy outcomes.

• EPZ-6438 (SKU A8221): Precision EZH2 Inhibition in Epigeneti

  2026-05-11

  This article explores real-world laboratory scenarios where EPZ-6438 (SKU A8221) addresses challenges in cell viability, proliferation, and cytotoxicity assays. By integrating evidence-based Q&A, it demonstrates how this highly selective EZH2 inhibitor supports reproducible, data-driven workflows for biomedical researchers.

• Deferasirox: Oral Iron Chelator for Targeted Iron Metabolism

  2026-05-10

  Deferasirox is redefining research on iron overload and cancer by enabling precise control of cellular iron pools and metabolic stress responses. This article delivers a protocol-centric guide to experimental workflows, troubleshooting, and advanced applications—bridging recent insights into nutrient sensing and ferroptosis resistance.

• Cholesterol Impairs Lipid Nanoparticle Trafficking in Cells

  2026-05-09

  This study reveals that elevated cholesterol levels in lipid nanoparticles (LNPs) hinder their intracellular trafficking and cargo delivery by promoting aggregation in early endosomes. The research leverages a highly sensitive streptavidin–biotin-DNA tracking platform, offering mechanistic insight for optimizing LNP formulations in nucleic acid delivery applications.

• Meropenem Trihydrate in Resistance Phenotyping Workflows

  2026-05-08

  Meropenem trihydrate unlocks advanced, reproducible workflows for antibiotic resistance studies and robust infection modeling. Explore stepwise protocols, troubleshooting strategies, and the transformative impact of metabolomics-based resistance detection, all leveraging APExBIO’s rigorously validated carbapenem antibiotic.

• LY294002: Translational Leverage in PI3K Pathway and Beyond

  2026-05-08

  This article provides translational researchers with a mechanistic, evidence-driven framework for deploying LY294002—a potent, reversible class I PI3K inhibitor—in the interrogation of PI3K/Akt/mTOR signaling, autophagy, and apoptosis. Drawing from recent neuroinflammation and oncology studies, we discuss protocol optimization, emerging cross-domain applications, and next-generation experimental strategies. The narrative integrates primary literature, product intelligence, and competitive context, demonstrating how APExBIO’s LY294002 advances research beyond conventional use cases.

• A 83-01 (ALK-5 Inhibitor): Precision Control in Human Organo

  2026-05-07

  Explore how A 83-01, a selective ALK-5 inhibitor, enables refined modulation of TGF-β signaling for balancing self-renewal and differentiation in advanced human organoid research. Discover new assay strategies grounded in recent breakthroughs.

• Meropenem: A Carbapenem Benchmark for Resistance Modeling &

  2026-05-07

  Explore Meropenem, an ultra-broad-spectrum β-lactam antibiotic carbapenem, as a precision tool for dissecting resistance in Gram-negative and Gram-positive bacteria. This article uniquely focuses on translational assay design, protocol optimization, and practical insights for research models.

• Predicting Compound Mechanism Across Cell Lines Using ML Cla

  2026-05-06

  Warchal et al. critically evaluated machine learning classifiers for predicting compound mechanism of action (MoA) using high-content image data across genetically distinct cancer cell lines. Their findings reveal the strengths and limitations of ensemble-based and deep learning approaches, with important implications for phenotypic drug screening and translational cancer research.

• JC-1 Fluorescent Probe: Optimizing Mitochondrial Potential A

  2026-05-06

  JC-1 enables high-sensitivity, ratiometric assessment of mitochondrial membrane potential, powering advanced apoptosis and bioenergetics research. This guide delivers actionable protocols, experimental troubleshooting, and translational insights derived from cutting-edge cancer studies, ensuring robust data and reproducibility for cell-based assays.

• Comparative Antibacterial Activity of Cefoperazone and New β

  2026-05-05

  This article analyzes Cullmann et al.'s landmark comparison of N-formimidoyl thienamycin (MK0787) with recently developed β-lactam antibiotics—including cefoperazone—against a diverse panel of resistant clinical isolates. The findings inform selection criteria for in vitro antimicrobial activity assays and resistance studies, highlighting both compound-specific advantages and methodological considerations.

• 2-APB in Calcium Signaling: Optimized Protocols and Innovati

  2026-05-05

  2-APB (2-aminoethoxydiphenyl borate) enables precise modulation of calcium dynamics for dissecting autophagy–apoptosis transitions and oxidative stress responses. Here, we translate the latest Bombyx mori findings into actionable workflows, troubleshooting insights, and advanced use-cases for cell fate research.

13479 records 1/899 page Next 12345 下5页 Last page